Performance analysis of Akebia Therapeutics (AKBA)
Annual Return
Over the past 3 years, AKBA has had an average annual return of -5.21%, underperforming the benchmark SPY, which returned +22.77% annual.
Over the past 5 years, AKBA has had an average annual return of -22.41%, underperforming the benchmark SPY, which returned +14% annual.
Over the past 10 years, AKBA has had an average annual return of -20.11%, underperforming the benchmark SPY, which returned +15.53% annual.
Since Mar 20, 2014, AKBA has had an average annual return of -23.99%, underperforming the benchmark SPY, which returned +14.06% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -41.79% | -15.31% | +53.12% | +115.28% | -74.50% | -19.26% | -55.68% | +14.24% | -62.80% | +42.82% | -19.42% | +11.01% |
| 2014 | |||||||||||
| -56.40% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.44% | -7.01% | +6.11% | -0.77% | -26.11% | -8.12% | -41.79% | ||||||
| 2025 | +17.84% | -17.40% | +3.75% | +25.59% | +25.69% | +20.18% | +1.17% | -14.78% | -13.01% | -19.06% | -28.50% | +1.86% | -15.31% |
| 2024 | +35.27% | -5.88% | +15.88% | -31.20% | -11.02% | -9.05% | +35.34% | +12.38% | -14.97% | +25.91% | +24.12% | -7.77% | +53.12% |
| 2023 | +9.26% | +33.90% | -33.54% | +61.90% | +14.71% | -12.05% | +82.51% | -16.77% | -18.04% | -22.72% | +20.30% | +17.13% | +115.28% |
| 2022 | -12.04% | +8.59% | -66.75% | -42.01% | -10.90% | -5.04% | +10.61% | -6.85% | -13.24% | -19.49% | +6.32% | +113.86% | -74.50% |
| 2021 | +15.73% | +6.75% | -2.16% | -5.76% | +10.04% | +7.98% | -34.86% | +19.03% | -2.00% | -0.37% | -5.58% | -16.55% | -19.26% |
| 2020 | +14.28% | +22.85% | -14.57% | +6.87% | +43.70% | +16.67% | -17.75% | -6.79% | -75.90% | -11.49% | +49.04% | -15.40% | -55.68% |
| 2019 | -0.39% | +32.12% | +12.50% | -26.24% | -26.34% | +8.76% | -13.40% | -1.46% | -5.11% | -4.84% | +68.65% | +0.47% | +14.24% |
| 2018 | -0.59% | -3.25% | -33.36% | -3.36% | +6.64% | +1.63% | +3.18% | -20.30% | +7.58% | -15.18% | +7.88% | -31.55% | -62.80% |
| 2017 | -3.67% | -0.08% | -8.20% | +43.27% | +1.68% | +7.23% | -8.21% | +26.92% | +17.49% | -7.72% | -14.27% | -4.44% | +42.82% |
Drawdown analysis of Akebia Therapeutics (AKBA)
The maximum drawdown for the AKBA was -99.14%, occurring on Nov 16, 2022. This drawdown has not yet recovered.
The current AKBA drawdown is -96.79%.
Since Mar 20, 2014 AKBA has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 3 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.14% | Jun 20, 2014 | 2118 | Nov 16, 2022 | Ongoing | Ongoing | Ongoing |
| -36.84% | Mar 20, 2014 | 16 | Apr 11, 2014 | 5 | Apr 21, 2014 | 21 |
| -21.82% | Apr 21, 2014 | 20 | May 19, 2014 | 14 | Jun 9, 2014 | 34 |
| -4.91% | Jun 9, 2014 | 6 | Jun 17, 2014 | 3 | Jun 20, 2014 | 9 |